---
title: "Teva Pharmaceutical Industries Limited (TEVA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/TEVA.US.md"
symbol: "TEVA.US"
name: "Teva Pharmaceutical Industries Limited"
industry: "制药"
---

# Teva Pharmaceutical Industries Limited (TEVA.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [www.tevapharm.com](https://www.tevapharm.com) |

## Company Profile

泰瓦制药工业有限公司在美国、欧洲、以色列及国际市场开发、生产、销售和分销仿制药及其他药品和生物制药产品。它提供多种剂型的仿制药，如片剂、胶囊、注射剂、吸入剂、液体、透皮贴剂、软膏和乳膏；无菌产品、激素、高效药物和细胞毒性物质的注射剂和固体剂型；以及与医疗器械和组合产品的仿制产品。该公司还专注于中枢神经系统（CNS）、呼吸系统和肿瘤领域。它提供活性药物成分以及合同生产服务；并运营一个外部授权平台，为其他制药公司提供产品组合

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:15.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 47 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.32% |  |
| Net Profit YoY | 186.03% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.04 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 39.85B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 17.26B |  |


**Multi Score**: C

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 21.23% | A |
| Profit Margin | 8.17% | B |
| Gross Margin | 51.79% | B |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.32% | C |
| Net Profit YoY | 186.03% | A |
| Total Assets YoY | 3.62% | C |
| Net Assets YoY | 38.36% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1223.97% | B |
| OCF YoY | 4.32% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.43 | C |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 80.58% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Teva Pharmaceutical Industries Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "21.23%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "8.17%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "51.79%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.32%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "186.03%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.62%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "38.36%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1223.97%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "4.32%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.43",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "80.58%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 礼来 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 罗氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 诺华制药 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 28.27 | 40/257 | 51.07 | 45.59 | 28.51 |
| PB | 5.04 | 137/257 | 4.71 | 3.30 | 3.06 |
| PS (TTM) | 2.31 | 61/257 | 2.04 | 1.25 | 1.13 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-17T05:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 8 | 57% |
| Overweight | 4 | 29% |
| Hold | 0 | 0% |
| Underweight | 1 | 7% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 34.22 |
| Highest Target | 40.00 |
| Lowest Target | 28.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/TEVA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/TEVA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/TEVA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.